title: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
authors.affiliation: Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. shankarl@mail.nih.gov
authors.forename: Lalitha K
authors.initials: LK
authors.lastname: Shankar
authors.forename: John M
authors.initials: JM
authors.lastname: Hoffman
authors.forename: Steve
authors.initials: S
authors.lastname: Bacharach
authors.forename: Michael M
authors.initials: MM
authors.lastname: Graham
authors.forename: Joel
authors.initials: J
authors.lastname: Karp
authors.forename: Adriaan A
authors.initials: AA
authors.lastname: Lammertsma
authors.forename: Steven
authors.initials: S
authors.lastname: Larson
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
authors.forename: Barry A
authors.initials: BA
authors.lastname: Siegel
authors.forename: Annick
authors.initials: A
authors.lastname: Van den Abbeele
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Yap
authors.forename: Daniel
authors.initials: D
authors.lastname: Sullivan
mesh_terms: D002986:Clinical Trials as Topic / Q000592:standards*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards*; D049268:Positron-Emission Tomography / Q000379:methods / Q000592:standards*; D011379:Prognosis; D019275:Radiopharmaceuticals; D016896:Treatment Outcome; D014481:United States
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18